Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 15/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6152401 | 0.85 | HTR2A (0.59) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL7643807 | 0.74 | HTR2A (0.44) | HTR2ASLC6A4KCNH2SOS1SLC6A2 | |
| SCHEMBL7623848 | 0.72 | SOS1 (0.43) | HTR2ASLC6A4KCNH2SOS1SLC6A2 | |
| SCHEMBL6448614 | 0.69 | HTR2A (0.67) | HTR2ASLC6A4KCNH2SOS1SLC6A2 | |
| SCHEMBL6153430 | 0.68 | HTR2A (0.59) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL6451017 | 0.67 | HTR2A (0.67) | HTR2ASLC6A4KCNH2ADRA1ATAAR1 | |
| SCHEMBL7521053 | 0.66 | HTR2A (0.59) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL6151996 | 0.64 | HTR2A (0.59) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL7568036 | 0.64 | HTR2A (0.59) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL6153427 | 0.64 | HTR2A (0.59) | HTR2ASLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020107244-A1 | An antidepressant formulation consists of a biphenoxy or binaphthelenoxy compound as antidepressant, a 5-HT3 receptor antagonist and a carrier | PFIZER PRODUCTS INC. | 2002-08-08 | — | — | US | disclosed |
| US-20020099045-A1 | Combination treatment for depression | PFIZER PRODUCTS INC. | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107244-A1 | An antidepressant formulation consists of a biphenoxy or binaphthelenoxy compound as antidepressant, a 5-HT3 receptor antagonist and a carrier | HTR3A, HTR3E, HTR4 | HTR2A 11/4885SLC6A4 19/4885KCNH2 2974/4885 |
| US-20020099045-A1 | Combination treatment for depression | HTR5A, HTR1A, OPRL1 | HTR2A 4/4885SLC6A4 11/4885KCNH2 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.